Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of KTE-C19 in Adults With Refractory Aggressive Non-Hodgkin Lymphoma

NCT02348216 is registered in ClinicalTrials.gov with Kite, A Gilead Company as lead sponsor.

NCT NCT02348216
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02348216 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of KTE-C19 in Adults With Refractory Aggressive Non-Hodgkin Lymphoma
Lead sponsor
Kite, A Gilead Company
Phase
Phase 1/2
Overall status
Completed
Start date
April 21, 2015
Completion date
July 27, 2023
Enrollment
307 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

high grade b-cell lymphoma (hgbcl), primary mediastinal b-cell lymphoma (pmbcl), refractory diffuse large b cell lymphoma (dlbcl), relapsed diffuse large b-cell lymphoma, transformed follicular lymphoma (tfl)